Teva has suspended the sale of its sumatriptan iontophoretic transdermal system (Zecuity) patch while the FDA investigates the risk for serious burns and potential permanent scarring related to use of the product.
In addition to the voluntary suspension, Teva has initiated a pharmacy-level recall of the product.
“Since marketing of the Zecuity patch began in September 2015, a large number of patients have reported they experienced burns or scars on the skin where the patch was worn,”